Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

For information on rights and reprints, contact subscriptions@lawyerly.com.au